January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 
January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 

Pipeline Two Icon Pipeline Two Header

Cambridge Healthtech Institute’s 5th Annual
Bispecific Antibody Therapeutics
Engineering Multispecificity
January 21-22, 2016

Creating bioactive molecules that are multivalent and multifunctional offers the promise of more effective therapies. Empowered antibodies bind to at least two molecular targets simultaneously, thereby delivering a highly potent therapeutic, particularly for cancer. The Bispecific Antibody Therapeutics meeting explores the challenges of engineering multispecificity to ensure stability and efficacy, and reviews the numerous forms of multispecific antibodies in development, including next-generation antibody formats. Case studies highlight safety issues, along with preclinical and clinical data. Join colleagues from around the world in this discussion of the exciting breakthroughs in engineering antibodies, and see how cancer and other applications are advancing into a true therapeutic revolution.

Preliminary Agenda


Advancement in Novel Bispecific Biotherapeutics: Challenges and Opportunities

Rakesh Dixit, Ph.D., DABT, Vice President, Research & Development, and Global Head, Biologics Safety Assessment, MedImmune

Bispecific Antibodies: Strategies, Considerations and Challenges

Christoph Spiess, Ph.D., Senior Scientist, Antibody Engineering, Genentech, Inc.


CrossMAb Vh-Vl

Jörg Thomas Regula, Ph.D., Head, Functional Characterization, Large Molecule Research, Roche Pharma Research & Early Development

Facile Generation of Common Light Chain Bispecific Antibodies

Paul Widboom, Ph.D., Scientist, Antibody Engineering, Adimab LLC

Bispecific FynomAbs: Novel Modes of Action through Tailored Architecture

Isabella Attinger-Toller, Ph.D., Director, Pharmacology, in vivo Pharmacology, Covagen AG, one of the Janssen Pharmaceutical Companies of Johnson & Johnson

Development of Bispecific AffiMab Antibody Engineered Using Affibody Molecule for Target Therapy

Kyu-Tae Kim, Ph.D., Director, ADDs Program, AbClon


Preclinical Development of the Tribody Tb535, a 5T4 Targeting Bispecific T Cell Engager

Nico Mertens, Ph.D., Vice President and Head, Antibody Research, R&D, Biotecnol Ltd.

A Novel Tissue-Specific Agonist of the FGF21 Pathway for the Treatment of Type 2 Diabetes

James Ernst, Ph.D., Senior Scientist, Protein Therapeutics, Genentech, Inc.

Getting TRAIL Back on Track: RG7386, A Novel Bispecific FAP-DR5 Antibody for the Treatment of Cancer

Oliver Krieter, Ph.D., Senior Translational Medicine Leader, pRED Innovation Center Penzberg, Roche


Modular mAb2 Technology Enables Rapid Assessment of Bispecific Modality

Haijun Sun, Ph.D., Vice President, Tumour Biology and Protein Sciences, F-star Biotechnology

The BEAT Bispecific Antibody Technology: An Industry-Applicable Platform for the Development of Highly Potent Biologics

Greg Elson, Ph.D., Vice President, Biologics Manufacturing, Glenmark Pharmaceuticals

For questions about the meeting, please contact:

For partnering & sponsorship information, please contact:

Mary Ruberry
Senior Conference Director
Cambridge Healthtech Institute
Phone: 781-972-5421
Email: mruberry@healthtech.com

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470
Email: jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470
Email: dinerstein@healthtech.com